Policy, industry, and capital converge: a critical window emerges for innovative drugs

Amid the confluence of multiple positive factors, the long-term growth thesis for innovative pharmaceuticals continues to strengthen, with rising certainty in valuation recovery and earnings realization in the second half of the year, further bolstering market confidence in the sector’s long-term growth prospects.

Zhitong Finance07:06

Wuxi Biologics (Cayman) Stock Slips 6.0% in Hong Kong

Dow Jones16:30

Wuxi Bio (02269.HK): Innovation Drives Rapid Business Growth; Bispecific and Multispecific Antibodies Expected to Become Key Growth Engine

Newly signed projects continue to grow, and the pipeline funnel effect is evident, providing certainty for the company’s sustained business growth: leveraging its industry-leading technological advantages, exceptional team execution capabilities, and continuously deepening global footprint, the company continues to secure a substantial volume of newly signed projects,

SDIC SecuritiesJul 16 16:57

Hong Kong Stock Market Concept Tracker | Experimental Monkey Prices Soar to RMB 200,000! Multiple Companies Report Severe Shortages as CRO Sector Orders Rebound Broadly (Including Related Stocks)

Recently, with increased activity in new drug development, laboratory monkeys have once again become scarce, driving their price up to RMB 200,000 per animal.

Zhitong FinanceJul 16 07:49

Accelerated partnerships and influx of industry giants propel AI-driven drug discovery into commercial fast lane

A Goldman Sachs research report indicates that AI can shorten drug time-to-market by approximately 20% to 25%, reduce the R&D process by about three years, and potentially lower overall development costs by roughly 25% to 30%.

Zhitong FinanceJul 16 07:08

Dual catalysts of innovative drugs going global and accelerated policy support drive strong gains across Hong Kong-listed biotech stocks, with Zhaoyan New Drug surging nearly 22%.

① What is the pass rate for the formal review of innovative drugs under the National Reimbursement Drug List (NRDL) and commercial insurance in 2026? ② How have outbound licensing deals for China’s innovative drugs performed in the first half of this year?

cls.cnJul 15 11:30